MediGene (ETR:MDG1) has been given a €17.00 ($19.77) price target by research analysts at Baader Bank in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock. Baader Bank’s price objective indicates a potential upside of 81.92% from the stock’s previous close.

Separately, Independent Research set a €15.50 ($18.02) price target on shares of MediGene and gave the stock a “neutral” rating in a research note on Friday, August 10th.

MediGene stock traded down €0.18 ($0.21) during midday trading on Wednesday, reaching €9.39 ($10.92). The stock had a trading volume of 127,595 shares, compared to its average volume of 306,207. MediGene has a 52-week low of €8.53 ($9.92) and a 52-week high of €19.27 ($22.41).

MediGene Company Profile

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.

Further Reading: How to Invest in the Dividend Aristocrat Index

Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.